Reported Saturday, Biogen's Litifilimab Meets Primary Endpoint In Phase 2 AMETHYST Trial, Showing 11.8% Greater Reduction In CLE Disease Activity Versus Placebo At Week 16

Biogen's investigational drug, litifilimab, successfully met the primary endpoint in the Phase 2 AMETHYST trial, demonstrating an 11.8% greater reduction in cutaneous lupus erythematosus (CLE) disease activity compared to placebo at Week 16. This follows positive results from the Phase 2 LILAC study, making litifilimab the only program with consistent efficacy in multiple CLE studies. If approved, it could become the first targeted therapy for this serious autoimmune disease.